Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia
Abstract The FDA recently approved eight targeted therapies for acute myeloid leukemia (AML), including the BCL-2 inhibitor venetoclax. Maximizing efficacy of these treatments requires refining patient selection. To this end, we analyzed two recent AML studies profiling the gene expression and ex vi...
Guardado en:
Autores principales: | Brian S. White, Suleiman A. Khan, Mike J. Mason, Muhammad Ammad-ud-din, Swapnil Potdar, Disha Malani, Heikki Kuusanmäki, Brian J. Druker, Caroline Heckman, Olli Kallioniemi, Stephen E. Kurtz, Kimmo Porkka, Cristina E. Tognon, Jeffrey W. Tyner, Tero Aittokallio, Krister Wennerberg, Justin Guinney |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f6bd5ff98ce1490bb82d669c7207b895 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways.
por: Jing Tang, et al.
Publicado: (2013) -
Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts.
por: Fariba Némati, et al.
Publicado: (2014) -
Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL
por: Reut Yosef, et al.
Publicado: (2016) -
Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
por: Olli Dufva, et al.
Publicado: (2018) -
Prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer
por: Ki-Tae Hwang, et al.
Publicado: (2021)